RT @AnastasiaSMihai: Congratulations @jordy_bc & coauthors for yr @JACCJournals & teasing impt data from TOPCAT trial 👏👏 Importance of Cli…
RT @AnastasiaSMihai: Congratulations @jordy_bc & coauthors for yr @JACCJournals & teasing impt data from TOPCAT trial 👏👏 Importance of Cli…
RT @Office_j: 【HFpEFに3つの表現型?:TOPCAT追加解析/ JACC HF】 1)若年、喫煙癖多、心血管基質的異常小、2)高齢、AF合併、CV気質的異常、自己免疫マーカー高値 [?]、3)肥満、CKD、高レニン、TNF-α高値——。2,3で死亡率高。スピ…
RT @Office_j: 【HFpEFに3つの表現型?:TOPCAT追加解析/ JACC HF】 1)若年、喫煙癖多、心血管基質的異常小、2)高齢、AF合併、CV気質的異常、自己免疫マーカー高値 [?]、3)肥満、CKD、高レニン、TNF-α高値——。2,3で死亡率高。スピ…
RT @nishiki8885: なんか、これってPAFのフェノタイプにも似てますね。 高レニンがあるような病態ではスピロノラクトンが効く? これは論文読まねば。
RT @AnastasiaSMihai: Congratulations @jordy_bc & coauthors for yr @JACCJournals & teasing impt data from TOPCAT trial 👏👏 Importance of Cli…
Congratulations @jordy_bc & coauthors for yr @JACCJournals & teasing impt data from TOPCAT trial 👏👏 Importance of Clinical Phenogroups in #HFpEF Timely for International Aldosterone Conference in #SF next mth @adina_turcu @DrJMLuther @moragjyoun
なんか、これってPAFのフェノタイプにも似てますね。 高レニンがあるような病態ではスピロノラクトンが効く? これは論文読まねば。
RT @Office_j: 【HFpEFに3つの表現型?:TOPCAT追加解析/ JACC HF】 1)若年、喫煙癖多、心血管基質的異常小、2)高齢、AF合併、CV気質的異常、自己免疫マーカー高値 [?]、3)肥満、CKD、高レニン、TNF-α高値——。2,3で死亡率高。スピ…
RT @Office_j: 【HFpEFに3つの表現型?:TOPCAT追加解析/ JACC HF】 1)若年、喫煙癖多、心血管基質的異常小、2)高齢、AF合併、CV気質的異常、自己免疫マーカー高値 [?]、3)肥満、CKD、高レニン、TNF-α高値——。2,3で死亡率高。スピ…
RT @Office_j: 【HFpEFに3つの表現型?:TOPCAT追加解析/ JACC HF】 1)若年、喫煙癖多、心血管基質的異常小、2)高齢、AF合併、CV気質的異常、自己免疫マーカー高値 [?]、3)肥満、CKD、高レニン、TNF-α高値——。2,3で死亡率高。スピ…
RT @Office_j: 【HFpEFに3つの表現型?:TOPCAT追加解析/ JACC HF】 1)若年、喫煙癖多、心血管基質的異常小、2)高齢、AF合併、CV気質的異常、自己免疫マーカー高値 [?]、3)肥満、CKD、高レニン、TNF-α高値——。2,3で死亡率高。スピ…
RT @Office_j: 【HFpEFに3つの表現型?:TOPCAT追加解析/ JACC HF】 1)若年、喫煙癖多、心血管基質的異常小、2)高齢、AF合併、CV気質的異常、自己免疫マーカー高値 [?]、3)肥満、CKD、高レニン、TNF-α高値——。2,3で死亡率高。スピ…
2)がリハビリでも手強い感じです。運動療法まで進みにくい…
【HFpEFに3つの表現型?:TOPCAT追加解析/ JACC HF】 1)若年、喫煙癖多、心血管基質的異常小、2)高齢、AF合併、CV気質的異常、自己免疫マーカー高値 [?]、3)肥満、CKD、高レニン、TNF-α高値——。2,3で死亡率高。スピロノラクトンは3で著効。 https://t.co/gDsyYPvVvM https://t.co/PMBSwijzg7
HFpEF: 3 phenogroups; 1- young, smokers, & LVH 2- elderly, A-Fib, & LVH 3- obesity, DM, CKD, & LVH Clinical Phenogroups in HFpEF Detailed Phenotypes, Prognosis, and Response to Spironolactone: https://t.co/EoQ7rpLrbX https://t.co/Z8euUgSfTu
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
RT @JTLLERGO: Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spiro…
Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone (TOPCAT substudy) @JACCJournals @secardiologia @SACardiologia https://t.co/sNsgJqBEME https://t.co/lupo72tahS
"Latent class analysis" improves on subgroup analysis for translation of clinical trial (population based) treatment effects for patients who meet latent class definitions. Monitoring safety/efficacy mandatory for all, "n of 1" trials if unclassifiable or
RT @AndrewJSauer: Excellent TOPCAT analysis. Who benefits spiro? Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction | J…
RT @DrRajivsankar: https://t.co/2VXscEY6zT Excellent article on Clinical phenotypes of #HFpEF #heartfailure and responses to spironolactone…
RT @AndrewJSauer: Excellent TOPCAT analysis. Who benefits spiro? Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction | J…
RT @DrRajivsankar: https://t.co/2VXscEY6zT Excellent article on Clinical phenotypes of #HFpEF #heartfailure and responses to spironolactone…
RT @DrRajivsankar: https://t.co/2VXscEY6zT Excellent article on Clinical phenotypes of #HFpEF #heartfailure and responses to spironolactone…
RT @DrRajivsankar: https://t.co/2VXscEY6zT Excellent article on Clinical phenotypes of #HFpEF #heartfailure and responses to spironolactone…
RT @DrRajivsankar: https://t.co/2VXscEY6zT Excellent article on Clinical phenotypes of #HFpEF #heartfailure and responses to spironolactone…
RT @AndrewJSauer: Excellent TOPCAT analysis. Who benefits spiro? Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction | J…
RT @DrRajivsankar: https://t.co/2VXscEY6zT Excellent article on Clinical phenotypes of #HFpEF #heartfailure and responses to spironolactone…
RT @DrRajivsankar: https://t.co/2VXscEY6zT Excellent article on Clinical phenotypes of #HFpEF #heartfailure and responses to spironolactone…
RT @DrRajivsankar: https://t.co/2VXscEY6zT Excellent article on Clinical phenotypes of #HFpEF #heartfailure and responses to spironolactone…
RT @DrRajivsankar: https://t.co/2VXscEY6zT Excellent article on Clinical phenotypes of #HFpEF #heartfailure and responses to spironolactone…
RT @DrRajivsankar: https://t.co/2VXscEY6zT Excellent article on Clinical phenotypes of #HFpEF #heartfailure and responses to spironolactone…
RT @DrRajivsankar: https://t.co/2VXscEY6zT Excellent article on Clinical phenotypes of #HFpEF #heartfailure and responses to spironolactone…
RT @AndrewJSauer: Excellent TOPCAT analysis. Who benefits spiro? Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction | J…
Excellent TOPCAT analysis. Who benefits spiro? Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction | JACC: Heart Failure https://t.co/dIW1wwBHXh
RT @DrRajivsankar: https://t.co/2VXscEY6zT Excellent article on Clinical phenotypes of #HFpEF #heartfailure and responses to spironolactone…
RT @DrRajivsankar: https://t.co/2VXscEY6zT Excellent article on Clinical phenotypes of #HFpEF #heartfailure and responses to spironolactone…
RT @DrRajivsankar: https://t.co/2VXscEY6zT Excellent article on Clinical phenotypes of #HFpEF #heartfailure and responses to spironolactone…
At last!
RT @DrRajivsankar: https://t.co/2VXscEY6zT Excellent article on Clinical phenotypes of #HFpEF #heartfailure and responses to spironolactone…
RT @DrRajivsankar: https://t.co/2VXscEY6zT Excellent article on Clinical phenotypes of #HFpEF #heartfailure and responses to spironolactone…
RT @DrRajivsankar: https://t.co/2VXscEY6zT Excellent article on Clinical phenotypes of #HFpEF #heartfailure and responses to spironolactone…
RT @DrRajivsankar: https://t.co/2VXscEY6zT Excellent article on Clinical phenotypes of #HFpEF #heartfailure and responses to spironolactone…
https://t.co/2VXscEY6zT Excellent article on Clinical phenotypes of #HFpEF #heartfailure and responses to spironolactone https://t.co/RbpswoW82P
RT @jordy_bc: Excited to see our paper posted online @JACCJournals #JACCHF! We asked: were there differences in mechanistic biomarkers, car…
RT @jordy_bc: Excited to see our paper posted online @JACCJournals #JACCHF! We asked: were there differences in mechanistic biomarkers, car…
RT @Ricky_Turgeon: Very elegant analysis of HFpEF patients that sheds light on the different patterns of HFpEF that ring true with what we…
RT @MAROSFO: IC preservada ¿Diferentes fenotipos? ¿Diferentes mecanismos de acción? ¿Diferentes formas de responder a tratamientos dirigido…
Patients with #HFpEF have different clinical phenotypes, which may influence response to spironolactone. From TOPCAT, those with high renin, obesity/diabetes, and liver/renal injury appear to have a preferential response to MRA @JACCJournals #cardiotwitter
RT @Ricky_Turgeon: Very elegant analysis of HFpEF patients that sheds light on the different patterns of HFpEF that ring true with what we…
RT @Ricky_Turgeon: Very elegant analysis of HFpEF patients that sheds light on the different patterns of HFpEF that ring true with what we…
Very elegant analysis of HFpEF patients that sheds light on the different patterns of HFpEF that ring true with what we see in our HF clinic. Hopefully the PARAGON-HF investigators are paying attention & can add analyses to this discussion
Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone. JACC Heart Fail #cancer #epidemiology https://t.co/6ChvVUbNgn
RT @MAROSFO: IC preservada ¿Diferentes fenotipos? ¿Diferentes mecanismos de acción? ¿Diferentes formas de responder a tratamientos dirigido…
RT @MAROSFO: IC preservada ¿Diferentes fenotipos? ¿Diferentes mecanismos de acción? ¿Diferentes formas de responder a tratamientos dirigido…
RT @MAROSFO: IC preservada ¿Diferentes fenotipos? ¿Diferentes mecanismos de acción? ¿Diferentes formas de responder a tratamientos dirigido…
RT @jordy_bc: Excited to see our paper posted online @JACCJournals #JACCHF! We asked: were there differences in mechanistic biomarkers, car…
RT @jordy_bc: Excited to see our paper posted online @JACCJournals #JACCHF! We asked: were there differences in mechanistic biomarkers, car…
RT @jordy_bc: Excited to see our paper posted online @JACCJournals #JACCHF! We asked: were there differences in mechanistic biomarkers, car…
RT @jordy_bc: Excited to see our paper posted online @JACCJournals #JACCHF! We asked: were there differences in mechanistic biomarkers, car…
RT @MAROSFO: IC preservada ¿Diferentes fenotipos? ¿Diferentes mecanismos de acción? ¿Diferentes formas de responder a tratamientos dirigido…
RT @jordy_bc: Excited to see our paper posted online @JACCJournals #JACCHF! We asked: were there differences in mechanistic biomarkers, car…
RT @jordy_bc: Excited to see our paper posted online @JACCJournals #JACCHF! We asked: were there differences in mechanistic biomarkers, car…
RT @jordy_bc: Excited to see our paper posted online @JACCJournals #JACCHF! We asked: were there differences in mechanistic biomarkers, car…
Diferentes grupos de IC https://t.co/F0x561myvK